Product Information
RIFABUTIN 150 MG CAPSULE is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $8.1363 per EA under NDC 59762135001. Its NADAC has been published 359 times since Nov 19, 2014.
FDA first approved this application on Dec 23, 1992. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762135001
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIFABUTINApproval Type
Authorized Generic (NDA)
FDA Application
NDA050689FDA Approved
12/23/1992
TE Code
AB
On Market Since
4/7/2014
Pharmacological Classes
Price Statistics
The NADAC for RIFABUTIN 150 MG CAPSULE has been published 359 times since Nov 19, 2014, and over the history we have for it it has declined 38.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.1363 per EA |
|---|---|
| All-time high | $13.7705 (Jul 15, 2015) |
| All-time low | $7.3273 (Jun 19, 2024) |
| 52-week high | $9.6009 |
| 52-week low | $8.1008 |
| Median price | $11.9592 |
| Average price | $11.1728 |
| Largest weekly change | -18.0% (May 22, 2024) |
| Weeks tracked | 359 |
| Tracking since | Nov 19, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the rifabutin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rifabutin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIFABUTIN 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIFABUTIN 150 MG CAPSULE, manufactured by Mylan Pharmaceuticals Inc., is $8.1363 per EA (NDC 59762135001), effective Sep 30, 2026.
How has the price of RIFABUTIN 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIFABUTIN 150 MG CAPSULE has declined 38.4%. It has been tracked across 359 weekly CMS publications since Nov 19, 2014.
What are the highest and lowest recorded NADAC prices for RIFABUTIN 150 MG CAPSULE?
Since Nov 19, 2014, the NADAC for RIFABUTIN 150 MG CAPSULE has ranged from a low of $7.3273 (Jun 19, 2024) to a high of $13.7705 (Jul 15, 2015), with a median of $11.9592 per EA.
Are there cheaper alternatives to RIFABUTIN 150 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of RIFABUTIN 150 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RIFABUTIN 150 MG CAPSULE?
RIFABUTIN 150 MG CAPSULE (NDC 59762135001) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.